📰 Orca Bio News
Orca Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Orca Bio. Real-time updates on events, politics, business and more.
February 25, 2024
Encouraging data with RFS, OS, and NRM for Orca-T was also matched in a population of patients with hematologic cancers aged 55 years and older.
December 12, 2023
The high-precision cellular product Orca-Q demonstrated early signals of clinical activity as well as an acceptable safety profile for patients undergoing haploidentical stem cell transplantation without posttransplant cyclophosphamide.
December 10, 2023
– Orca-T, Orca Bio’s lead investigational high-precision cell therapy, showed similar results in older patients undergoing myeloablative conditioning as seen in younger patients across disease control, non-relapse mortality and overall survival –– Orca-T in older patients given a reduced intensity conditioning regim...
December 9, 2023
Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.
March 15, 2023
Jonathan MacQuitty talks about cell and gene therapy shortcomings and the challenges for private companies at different funding stages in 2023.
February 22, 2023
The global monoclonal gammopathy of undetermined significance (MGUS) management market is estimated to generate a market value of US$ 27 million in 2023 and a market value of US$ 53.11 million by 2033, growing at a CAGR of 7% from 2023 to 2033. The market for Monoclonal Gammopathy of Undetermined Significance (MGUS)...
February 16, 2023
– Three oral presentations showcase clinical evidence for Orca Bio’s promising pipeline of early- and late-stage high-precision cell therapies –– Orca-T demonstrated high relapse-free survival in recipients with fully matched donors and early potential in patients with mismatched donors –– Orca-Q showed improved gra...
January 30, 2023
/PRNewswire/ -- DelveInsights Acute Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and...
January 4, 2023
Business leaders and economists think the Capital Region will do just fine through at least the first half of this year
December 11, 2022
– Updated data from Phase 1b/2 trials include 151 patients with acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes and other hematological malignancies –– Relapse-free survival was 87% at one year in a group of 71 patients who received the preferred conditioning regimen being used in the P...